Globe Life (NYSE:GL) Price Target Raised to $225.00

Globe Life (NYSE:GL) had its target price boosted by TD Cowen from $215.00 to $225.00 in a report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

GL has been the subject of several other research reports. JPMorgan Chase & Co. raised their target price on shares of Globe Life from $181.00 to $201.00 and gave the stock an “overweight” rating in a research note on Tuesday. Keefe, Bruyette & Woods lifted their price objective on Globe Life from $180.00 to $192.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Morgan Stanley boosted their target price on Globe Life from $181.00 to $208.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Piper Sandler increased their target price on Globe Life from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 15th. Finally, Jefferies Financial Group raised their price target on Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.40.

Globe Life Stock Up 1.5%

GL opened at $173.64 on Wednesday. Globe Life has a 52 week low of $127.85 and a 52 week high of $191.55. The business has a 50 day moving average price of $169.07 and a two-hundred day moving average price of $152.91. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.38. The company has a market cap of $13.48 billion, a PE ratio of 11.53 and a beta of 0.47.

Globe Life (NYSE:GL) last announced its earnings results on Wednesday, July 22nd. The company reported $3.61 earnings per share for the quarter, missing the consensus estimate of $3.67 by ($0.06). Globe Life had a net margin of 19.58% and a return on equity of 20.73%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter last year, the business posted $3.05 earnings per share. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, research analysts anticipate that Globe Life will post 15.67 EPS for the current year.

Globe Life Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Monday, July 6th will be paid a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Monday, July 6th. Globe Life’s payout ratio is 9.13%.

Insider Transactions at Globe Life

In related news, CEO James Matthew Darden sold 4,663 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $153.88, for a total value of $717,542.44. Following the sale, the chief executive officer owned 58,451 shares of the company’s stock, valued at approximately $8,994,439.88. This represents a 7.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas Peter Kalmbach sold 15,637 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $153.65, for a total value of $2,402,625.05. Following the sale, the chief financial officer owned 45,335 shares in the company, valued at approximately $6,965,722.75. This trade represents a 25.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 90,187 shares of company stock worth $14,299,874. Corporate insiders own 2.11% of the company’s stock.

Institutional Trading of Globe Life

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Compound Planning Inc. grew its holdings in shares of Globe Life by 4.3% during the fourth quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock worth $275,000 after buying an additional 82 shares in the last quarter. Root Financial Partners LLC raised its position in shares of Globe Life by 23.3% in the first quarter. Root Financial Partners LLC now owns 439 shares of the company’s stock valued at $61,000 after buying an additional 83 shares during the last quarter. Transcend Capital Advisors LLC lifted its stake in shares of Globe Life by 3.9% during the fourth quarter. Transcend Capital Advisors LLC now owns 2,265 shares of the company’s stock valued at $317,000 after buying an additional 84 shares during the period. Natural Investments LLC lifted its stake in shares of Globe Life by 2.6% during the fourth quarter. Natural Investments LLC now owns 3,452 shares of the company’s stock valued at $482,000 after buying an additional 87 shares during the period. Finally, Parallel Advisors LLC boosted its position in Globe Life by 5.6% during the fourth quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock worth $231,000 after acquiring an additional 87 shares during the last quarter. 81.61% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Globe Life

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: Keefe, Bruyette & Woods trimmed its price target only modestly to $190 from $192 and kept an outperform rating, implying roughly 9% upside from recent levels. Benzinga article
• Positive Sentiment: TD Cowen also reiterated a bullish view, forecasting strong price appreciation for Globe Life (GL). American Banking News article
• Positive Sentiment: Management raised its 2026 net operating EPS guidance to $15.55-$15.95 and lifted share repurchases to $670 million-$700 million, signaling confidence in future earnings and capital returns. Seeking Alpha article
• Neutral Sentiment: Globe Life’s Q2 revenue came in roughly in line with expectations, and underwriting income remained strong, showing the core business is still performing acceptably despite some headwinds. Reuters article
• Negative Sentiment: Q2 earnings of $3.61 per share missed the consensus estimate of $3.67, and several reports pointed to softer sales and rising expenses as reasons for investor concern. MSN article

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.